Rituximab-induced interstitial lung disease: five case reports

  • Naqibullah M
  • Shaker S
  • Bach K
  • et al.
N/ACitations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rituximab (RTX), a mouse/human chimeric anti-CD20 IgG1 monoclonal antibody has been effectively used as a single agent or in combination with chemotherapy regimen to treat lymphoma since 1997. In addition, it has been used to treat idiopathic thrombocytopenic purpura, systemic lupus erythematous, rheumatoid arthritis, and autoimmune hemolytic anemia. Recently, RTX has also been suggested for the treatment of certain connective tissue disease-related interstitial lung diseases (ILD) and hypersensitivity pneumonitis. Rare but serious pulmonary adverse reactions are reported. To raise awareness about this serious side effect of RTX treatment, as the indication for its use increases with time, we report five cases of probable RTX-ILD and discuss the current literature on this potentially lethal association.

Cite

CITATION STYLE

APA

Naqibullah, M., Shaker, S. B., Bach, K. S., & Bendstrup, E. (2015). Rituximab-induced interstitial lung disease: five case reports. European Clinical Respiratory Journal, 2(1), 27178. https://doi.org/10.3402/ecrj.v2.27178

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free